Axovant rises after FDA grants rare pediatric disease tag to gene therapy

Sio Gene Therapies

13/10/2020 13:02

** Shares of gene therapies developer  AXGT.O  rise 5% to
$3.87 premarket 
    ** FDA grants Rare Pediatric Disease tag to AXO-AAV-GM2,
co's investigational gene therapy for GM2 gangliosidosis, also
known as Tay-Sachs and Sandhoff disease  urn:newsml:reuters.com:*:nGNX1ShSyY
    ** GM2 gangliosidosis is a rare genetic disorder that
progressively destroys nerve cells in the brain and spinal cord
    ** Tay-Sachs and Sandhoff disease has no current treatment
    ** AXO-AAV-GM2 also has Orphan Drug status
    ** Stock down 28% this year, as of last close 

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))